Nufloxib

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

Norfloxacin

Dostępny od:

Alphapharm Pty Ltd

Klasa:

Medicine Registered

Ulotka dla pacjenta

NUFLOXIB
1
NUFLOXIB
_contains the active ingredient norfloxacin_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Nufloxib.  It does
not contain all the available
information.
It does not take the place of talking
to your doctor or pharmacist.
All medicines have risks and
benefits.  Your doctor has weighed
the risks of you taking Nufloxib
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT NUFLOXIB IS USED
FOR
The name of your medicine is
Nufloxib.  It contains the active
ingredient norfloxacin.
Nufloxib is an antibiotic that belongs
to a group of medicines called
quinolones.  Nufloxib works by
killing the bacteria that are causing
your infection in different parts of
the body.
Nufloxib is also used to prevent
chronic (long-term) urinary tract
infections in adults.
Nufloxib will not work against
infections caused by viruses, such as
colds or the flu.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY NUFLOXIB HAS
BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed
Nufloxib for another reason.
Nufloxib is not addictive.
This medicine is available only with
a doctor's prescription.
BEFORE YOU TAKE
NUFLOXIB
_WHEN YOU MUST NOT TAKE_
_NUFLOXIB_
DO NOT TAKE NUFLOXIB IF YOU HAVE
AN ALLERGY TO
*
other products containing
norfloxacin (such as Noroxin,
Norflohexal, Insensye)
*
any other quinolone antibiotic
such as Avelox, C-Flox
*
any of the ingredients listed at the
end of this leaflet.
Some of the symptoms of an allergic
reaction may include asthma,
wheezing, shortness of breath,
swelling of the face, lips or tongue,
which may cause difficulty in
swallowing or breathing. Symptoms
may also include skin rash, itching,
hives or joint pain.
DO NOT GIVE NUFLOXIB TO CHILDREN OR
TO GROWING TEENAGERS (

Charakterystyka produktu

NUFLOXIB 
_Norfloxacin _

PRODUCT INFORMATION 

NAME OF THE MEDICINE 

Active ingredient: 
Norfloxacin. 

Chemical name: 
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl) -3- 
   quinoline 
carboxylic 
acid 

Structural formula: 

Molecular formula: 
C
16
H
18
FN
3
O
3

Molecular Weight:  
319.34  
CAS: 
  70458-96-7 

DESCRIPTION 

Norfloxacin is a white to pale yellow crystalline powder.  It
is freely soluble in glacial acetic 
acid, and very slightly soluble in ethanol, methanol and water.  It
has a melting point of 
approximately 221
°C. 

Norfloxacin, a fluoroquinolone, differs from quinolones by having a
fluorine atom at the 6 
position and a piperazine moiety at the 7 position.  Examples of
antibacterial drugs which are 
quinolones include nalidixic acid and cinoxacin. 

Each tablet of Nufloxib contains 400 mg of norfloxacin and the
following inactive ingredients:   
microcrystalline cellulose, croscarmellose sodium,
colloidal anhydrous silica, magnesium 
stearate, hypromellose, titanium dioxide, propylene glycol, lactose,
macrogol 4000, and  
talc - purified. 

PHARMACOLOGY 

Synthetic antibacterial agent for oral administration; a
fluoroquinolone. 

MICROBIOLOGY  

Norfloxacin has _in vitro_ activity against a broad spectrum of
Gram-negative and some Gram-
positive aerobic bacteria.  Norfloxacin inhibits bacterial
deoxyribonucleic acid synthesis and 
is bactericidal.   
At the molecular level three specific events are attributed to
norfloxacin in _Escherichia coli_ 
cells: inhibition of the ATP dependent DNA supercoiling reaction
catalysed by DNA gyrase; 
inhibition of the relaxation of supercoiled DNA; promotion of double
stranded DNA breakage. 

Resistance to norfloxacin due to spontaneous mutation _in vitro_ is
a rare occurrence  
(range: 10
-9
 to 10
-12
 cells).  Resistance of the organism has developed during therapy 
with norfloxacin in less than 1% of patients trea